CURRICULUM VITAE DAVID WEILL, M.D. TITLE Principal, Weill Consulting Group **WORK ADDRESS** 5935 Magazine Street, New Orleans, Louisiana 70115 TELEPHONE (OFFICE) 504.558.4942 E-MAIL david@weillconsulting.com LICENSE California, Louisiana and Florida PLACE OF BIRTH New Orleans, Louisiana CITIZENSHIP U.S. MARITAL STATUS Married **UNDERGRADUATE EDUCATION** 1985 Bachelor of Arts, Political Science, Tulane University, New Orleans, LA Cum Laude GRADUATE EDUCATION 1990 M.D., Tulane University Medical School 6/90-6/93 Internship and Residency in Internal Medicine, Parkland Hospital, University of Texas - Southwestern POSTDOCTORAL TRAINING 7/93-6/96 Fellowship in Pulmonary and Critical Care Medicine and Lung Transplantation, University of Colorado at Denver and Health Sciences Center (UCDHSC) **HONORS AND AWARDS** 2010 Cystic Fibrosis Research Institute, Professional of the Year LICENSURE AND CERTIFICATION 1993 - 2003 American Board of Internal Medicine, Internal Medicine 1996 Diplomate in Pulmonary Disease (recertified until 2016) 2006 Diplomate in Critical Care Medicine **GRANTS** 2010-2012 National Institutes of Health, NHLBI, R34RFA-HL-10-016 PRESENT/PENDING (8 TOTAL) Antibody-mediated rejection in lung transplantation Principal investigator, 2.5% effort 2011-2014 National Institutes of Health, RC4, RFA-OD-10-005 Genome Transplant: A non-invasive sequencing-based method for detecting acute and chronic rejection of solid organ transplants Co-investigator, 5% effort (Principal Investigators: Hannah Valantine/Steve Quake) 2008-2012 APT Pharmaceuticals, Inc., CIS001 The goal of this study is to assess the effectiveness of inhaled cyclosporine in preventing chronic rejection following lung transplantation. Dr. Weill is the site Principal Investigator 5% effort, \$ 275,351 direct costs/yr A multi-center, randomized, double-blind, placebo-controlled study to demonstrate the efficacy and safety of cyclosporine inhalation solution (CIS) in improving bronchiolitis obliterans syndrome-free survival following lung transplantation 2008-2011 Program for Adult Care Excellence Cystic Fibrosis Foundation, WEILL08ACO Dr. Weill is the Principal Investigator The major goal of this project is to enhance the training of adult physicians in the care of adult patients with cystic fibrosis. 2001-2011 Cystic Fibrosis Center Grant, Cystic Fibrosis Foundation C011-09 Dr. Weill is the Co-Principal Investigator (Principal Investigator: Carlos Milla) The major goal of this project is to provide infrastructure support to the Stanford Cystic Fibrosis Center. 2009-2011 Translational Therapeutics Development Center Cystic Fibrosis Foundation Therapeutics, Inc MILLA09Y0 Dr. Weill is the Co-Principal Investigator, (Principal Investigator: Carlos Milla) The major goal of this project is to establish infrastructure support for a clinical trials network related to cystic fibrosis. 2007-2011 National Institutes of Health A Multi center Prospective Cohort Study Examining the Role of Protein C in Early ARDS Co – Investigator (Principal Investigator: Ann Weinacker) Goal: Participate in a multicenter trial examining primary graft injury after lung transplantation Responsibilities: Coordinate patient selection and monitoring with the PI 2011-2013 National Institutes of Health, Program Project Grant Elafin Therapy of Lung Disease Co-investigator (Principal Investigator: Marlene Rabinovitch) **APPOINTMENTS PROFESSIONAL** 7/96 -11/99 Medical Director, Lung and Heart – Lung Transplant Program Medical City Hospital Dallas, TX ACADEMIC 12/99 -5/02 Associate Professor of Medicine Medical Director, Lung and Heart – Lung Transplant Program University of Alabama – Birmingham 6/02 -11/05 Associate Professor of Medicine Associate Director, Lung and Heart – Lung Transplant Program University of Colorado Health Sciences Center 12/31/05 - 04/30/06 Acting Associate Professor Stanford University School of Medicine 05/01/06 - 07/31/11 Associate Professor of Medicine Medical Director, Lung and Heart – Lung Transplant Program Stanford University School of Medicine 08/01/11 - 7/1/16 Professor of Medicine Stanford University School of Medicine 12/05 -10/05 Director, Center for Advanced Lung Diseases **OTHER APPOINTMENTS** Medical Director, Lung and Heart - Lung Transplant Program, Stanford University Medical Center 9/08 - 7/13 Director, Adult Cystic Fibrosis Program, Stanford University School of Medicine **EDITORIAL BAORD** 1999 - 2009 Associate Editor, The Journal of Heart and Lung Transplantation, PEER REVIEW ACTIVITIES 2014 - Present American Journal of Respiratory and Critical Care Medicine 2014 - Present Journal of Toxicology and Environmental Health 2014 - Present Thorax 2014 - Present Critical Reviews in Toxicology 2013 - Present The New England Journal of Medicine 1996 - Present The Journal of Heart and Lung Transplantation 1996 - Present American Journal of Transplantation 1996 - Present The Journal of Chronic Obstructive Pulmonary Disease 1996 - Present Chest 1996 - Present Clinical Transplantation MAJOR COMMITTEE AND SERVICE RESPONSIBILITIES (ADMINISTRATION) (10 TOTAL) 2007-2008 Search Committee, Director, Adult Cystic Fibrosis Program, Stanford **DIVISIONAL** 2004-2005 Finance Committee, Division of Pulmonary and Critical Care, University of Colorado Health Sciences Center 2010-2012 Strategic Planning Committee, Department of Medicine, Stanford DEPARTMENTAL 2013-2015 Search Committee Chair, Surgical Director, Lung Transplantation, Cardiothoracic Surgery, Stanford SOM 2008-Present Quality Council (Co-Chair), Transplantation PPEC, Stanford 2010-2012 Faculty Fellow, Stanford 2008-2011 Quality Council (Co-Chair), Cardiothoracic Surgery, Stanford 2006-2007 Search Committee, Head, Thoracic Surgery, Cardiothoracic Surgery, Stanford 2007 Hand Hygiene Physician Task Force, Stanfordd 2006 Search Committee, Pediatric Pulmonary Biology Center Faculty Member, Stanford 2002-2005 Antimicrobial Subcommittee, Pharmacy and Therapeutics Committee, University of Colorado Health Sciences Center LEADERSHIP ROLES (3 TOTAL) 2009-2015 Director, Center for Advanced Lung Disease, Stanford University Medical Center 2009-2015 Medical Director, Lung and Heart – Lung Transplant Program, Stanford University Medical Center 2008-2013 Director, Adult Cystic Fibrosis Center, Stanford University Medical Center PROFESSIONAL SOCIETY LEADERSHIP ROLES (6 TOTAL) 2014-2016 Past Chair, Pulmonary Transplantation Council, International Society of Heart and Lung Transplantation 2012-2014 Chair, Pulmonary Transplantation Council, International Society of Heart and Lung Transplantation 2014-2015 Section Editor, ISHLT's reference guide for the work-up and diagnosis of common syndromes in thoracic organ transplant recipients 2009-2011 Vice-Chair, Pulmonary Transplantation Council, International Society of Heart and Lung Transplantation 2008-2011 Pulmonary Council Leader, Standard and Guidelines Committee, International Society of Heart and Lung Transplantation 2008-Present Member, Medical Advisory Board, California Transplant Donor Network April 14, 2014 Advances in Immunosuppression, International Society of Heart and Lung Transplantation, San Diego MEETING SESSION CHAIRMAN (4 TOTAL) April 13, 2011 ISHLT Academy: Core Competencies in Lung Transplantation, International Society of Heart and Lung Transplantation, San Diego April 23, 2009 The Lung Allocation System, International Society of Heart and Lung Transplantation, ParisAdvances in April 27, 2009 Immunosuppression, International Society of Heart and Lung Transplantation, San Francisco February 22,2003 Controversies in Cardiothoracic Transplantation, Cardiothoracic Transplantation: An International Update, Vail, CO April 6, 2000 Clinical Lung Transplantation, International Society for Heart and Lung Transplantation, Osaka, Japan COMMITTEE (7 TOTAL) 2014-2016 Member, Thoracic Committee, United Network for Organ Sharin 2008-2010 Member, Communications Committee, International Society of Heart and Lung Transplantation 2007-Present Abstract Reviewer, International Meeting, International Society of Heart and Lung Transplantation 2006-2008 Member, Membership and Professional Standards Committee, United Network for Organ Sharing 2005-2006 Member, National Lung Review Board, United Network for Organ Sharing 2003 Member, Working Group on Primary Lung Graft Failure, International Society of Heart and Lung Transplantation 2001 Member, Maximizing Cadaveric Organ Utilization, American Society of Transplantation **TEACHING RECORD** CURRICULUM DEVELOPMENT 2005-2015 Lung Transplant Fellowship Stanford University Medical Center 2002-2005 Lung Transplant Fellowship University of Colorado Health Sciences Center 1999-2002 Lung Transplant Fellowship University of Alabama – Birmingham 1999-2002 June 2007 United States Senate Environment and Public Works The Heath Effects of Asbestos GOVERNMENTAL CONSULTING (3 TOTAL) February 2005 United States Senate Judiciary Committee Testimony Asbestos and Mixed Dust Disease March 2005 Texas State Legislature Testimony House Bill 8 Regarding Asbestos and Silica 2012-Present Chair, Scientific Advisory Board National Sand, Stone, and Gravel Association **SCIENTIFIC CONSULTING PUBLICATIONS** PEER-REVIEWED ARTICLES (43 TOTAL) 1. Beaver TM, Fullerton DA, Weill D, and Grover FL. Colon perforation after lung transplantation. Annals of Thoracic Surgery 1996; 62:839-843. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 2. Terada LS, Hybertson BM, Weill D, and Repine JE. XO increases neutrophil adherence to endothelial cells by a dual mechanism. Journal of Applied Physiology 1997; 82(3):866-873. My role is this study was to provide technical support in the experimental model for the more senior researchers. My secondary role was to write the sections regarding the scientific methodology. 3. Badesch DB, Zamora MR, Weill D, and Schwarz MI. Pulmonary capillaritis: a possible histologic form of acute allograft rejection. Journal of Heart and Lung Transplantation 1998; 17(4):415-422. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 4. Weill D, Hodges TN, Torres F, and Zamora MR. Acute native lung hyperinflation is not associated with a poor outcome following single lung transplantation for emphysema. Journal of Heart and Lung Transplantation 1999; 18:1080-1087. 5. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, and Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999 May 5; 91(9):763-71. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 6. . Weill D, McGiffin DC, Zorn GL, Alexander CB, Early LJ, Kirklin JK, and Young KR. The utility of open lung biopsy following lung transplantation. Journal of Heart and Lung Transplantation 2000; 19(9):852-857. 7. Weill D, Mack MJ, Roth J, Swisher S, Proksch, Merritt J, and Nemunaitis J. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest 2000; 118:966-70. 8. Nemunaitis J, Swisher SG, Mack M, Weill D, Merritt J, and Roth J. Adenovirus- mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. Journal of Clinical Oncology 2000; 18(3):609-622. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 9. Schmidt F, McGiffin DC, Zorn G, Young KY, Weill D, and Kirklin JK. Management of congenital abnormalities of the donor lung. Annals of Thoracic Surgery 2001; 72(3):935-7. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 10. Weill D, Dey GC, Hicks RA, Young KR, Zorn GL, Kirklin JK, Early L, and McGiffin DC. A positive donor gram stain does not predict outcome following lung transplantation. Journal of Heart and Lung Transplantation 2002; 21(5):555-8. 11. Weill D, Lock BJ, Wewers DL, Young KR, Zorn GL, Early L, Kirklin JK, and McGifffin DC. Combination prophylaxis with ganciclovir and cytomegalovirus immune globulin after lung transplantation: Effective CMV prevention following daclizumab induction. American Journal of Transplantation 2003; 3(4):492-496. 12. Zorn GL, McGiffin DC, Young KR, Alexander CB, Weill D, and Kirklin JK. Pulmonary transplantation for advanced bronchioloalveolar carcinoma. Journal of Thoracic and Cardiovascular Surgery 2003; 125(1):45-8. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 13. Dransfield MT, Garver RI, and Weill D. Standardized guidelines for surveillance bronchoscopy reduce complications in lung transplant recipients. Journal of Heart and Lung Transplantation 2004; 23(1):110-4. 14. Zamora MR, Nicolls MR, Hodges TN, Marquesen J, Astor TL, Grazia T, and Weill D. Following Universal Prophylaxis with Intravenous Ganciclovir and Cytomegalovirus Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection Following Lung Transplantation. American Journal of Transplantation 2004 Oct; 4(10):1635-42. 15. Christie JD, Carby M, Bag R, Corris P, Hertz M, and Weill D. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part II: Definition. A Consensus Statement of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation 2005 Oct; 24(10):1454-9. 16. Astor TL, Weill D, Cool C, Teitlebaum I, Schwarz MI and Zamora MR. function. Journal of Heart and Lung Transplantation 2005; 24:2091-7. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions. 17. Mulligan MS, Shearon TH, Weill D, Pagani FD, Moore J, and Murray S. Heart and Lung Transplantation in the United States, 1997-2006. American Journal of Transplantation 2008 Apr; 8(4 Pt 2):977-87. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions. 18. Leung M, Rachakonda L, Weill D, and Hwang P. Outcomes of Sinus Surgery before Lung Transplantation for Cystic Fibrosis. American Journal of Rhinology 2008 Mar – Apr; 22(2): 192 – 6. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 19. Valentine VG, Weill D, Raper B, Lombard GA, LaPlace SG, Bonvillain RW, Seoane L, Taylor DE, Dhillon GS. Ganciclovir for Cytomegalovirus: A Call for Indefinite Prophylaxis in Lung Transplantation. Journal of Heart and Lung Transplantation 2008 Aug; 27(8):875-81. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions. 20. Liu V, Dhillon GS, and Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis 2010 Feb; 12(1):38-44. 21. Dhillon GS, Levitt J, Mallidi H, Valentine VG, Gupta MR, Sista R, and Weill D. Impact of Hepatitis B core antibody positive donors in lung and heart-lung transplantation: an analysis of the United Network for Organ Sharing database. Transplantation 2009; 88:842-846. 22. Valentine VG, Weill D, Lombard GA, LaPlace SG, Seoane L, Taylor DE, Dhillon GS. A Single Institution Study Evaluating the Utility of Surveillance Bronchoscopy Following Lung Transplantation. Journal of Heart and Lung Transplantation 2009 Jan; 28(1):14-20. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the 23. Choi JY, Khansaheb M, Joo NS, Krouse ME, Robbins RC, Weill D, and Wine JJ. Substance P stimulates airway submucosal gland secretion mainly via a CFTR – dependent process. Journal of Clinical Investigation 2009 May, 119(5):1189-200. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 24. Liu V, Zamora MR, Dhillon GS, and Weill D. Increasing Lung Allocation Scores Predict Worsened Survival among Lung Transplant Recipients. American Journal of Transplantation 2010 Apr; 10(4):915-20. 25. Chang W, Wei K, Jacobs SS, Upadhyay D, Weill D, and Rosen GD. SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. J Biol Chem. 2010 Mar 12;285(11):8196-206. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 26. Dhillon GS, Zamora MR, Roos JE, Sheahan D, Sista RR, van der Starre P, Weill D, Nicolls MR. Lung transplant airway hypoxia: a diathesis to fibrosis. Am J Respir Crit Care Med. 2010 Jul 15;182(2):230-6. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions. 27. Deuse T, Sista R, Weill D, Haddad F, Dhillon G, Robbins RC, and Reitz BA. Review of heart—lung transplantation at Stanford. Ann Thorac Surg 2010 Jul;90(1):329-37. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions. 28. Weill D, Dhillon G, Freyder L, Lefante J, and Glindmeyer H. Lung function, radiologic changes, and exposure: analysis of ATSDR data from Libby, Montana. European Respiratory Journal 2011 Aug; 38(2):376-83. 29. Liu V, Bhattacharya J, Weill D, Hunt S, and Hlatky MA. Persistent racial disparities in survival following heart transplantation. Circulation 2011 Apr 19;123(15):1642-9. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions. 30. Liu V, Weill D., Bhattacharya J. Racial Disparities in Survival After Lung Transplantation. Arch Surg 2011 Mar; 146(3):286-93. 31. Dhillon G, Valentine V, Levitt J, Gupta M, Duncan S, Seoane L, and Weill D. Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients. Clinical Transplantation. 2012 Jan-Feb; 26(1):105-10. 32. Diamond JM, Lederer DJ, Kawut SM, Lee J, Ahya VN, Bellamy S, Palmer SM, Lama VN, Bhorade S, Crespo M, Demissie E, Sonnett J, Wille K, Orens J, Sha PD, Weinacker A, Weill D, Kohl BA, Deutschman CC, Arcasoy S, Shah AS, Belpierio JA, Wilkes D, Reynolds JM, Ware LB, Christie JD. Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis. Am J Transplant 2011 Nov;11(11):2517-22. 33. Diamond JM, Meyer NJ, Feng R, Rushefski M, Lederer DJ, Kawut SM, Lee JC, Cantu E, Shah RJ, Lama VN, Bhorade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Weinacker A, Weill D, Arcasoy S, Shah PD, Belperio JA, Wilkes D, Ware LB, Palmer SM, Christie JD. Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. Am J Respi Crit Care Med 2012 Sep 15;186(6):546-52. 34. Diamond JM, Porteous MK, Cantu E, Meyer NJ, Shah RJ, Lederer DJ, Kawut SM, Lee J, Bellamy SL, Palmer SM, Lama VN, Bhorade SM, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, Weill D, Arcasoy S, Wilkes DS, Ware LB, Christie JD; Lung Transplant Outcomes Group. Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation. PLoS One 2012;7(12):e51932. 35. De Vlaminck I, Khush KK, Strehl C, Kohli B, Luikart H, Neff NF, Okamoto J, Snyder TM, Cornfield DN, Nicolls MR, Weill D, Bernstein D, Valantine HA, Quake SR. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell 2013 Nov 21;155(5):1178-87. 36. Maxwell BG, Levitt JE, Goldstein BA, Mooney JJ, Nicolls MR, Zamora M, Valentine V, Weill D, Dhillon GS. Impact of the lung allocation score on survival beyond 1 year. Am J Transplant. 2014 Oct; 14(10):2288-94. 37. Maxwell BG, Mooney JJ, Lee PH, Levitt JE, Chhatwani L, Nicolls MR, Zamora MR, Valentine V, Weill D, Dhillon GS. Increased resource utilization in lung transplant admissions in the Lung Allocation Score era. Am J Respir Crit Care Med. 2014 Dec 17. 38. Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson GA, Singer LG, Snell GI, Verleden GM, Zamora MR, Glanville AR. A consensus document for the selection of lung transplant candidates: 2014 – an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015 39. Iwijn De Vlaminck, Lance Martina, Michael Kertesza, Kapil Patel, Mark Kowarskya, Calvin Strehle, Garrett Cohene, Helen Luikart, Norma F. Neff, Jennifer Okamoto, Mark R. Nicolls, David Cornfield, Weill D, Hannah Valantine, Kiran K. Khush, and Stephen R. Quake. Noninvasive monitoring of infection and rejection after lung transplantation. PNAS. 2015 Oct;112(43):13336-41. 40. Hill C, Maxwell B, Boulate D, Haddad F, Ha R, Afshar K, Weill D, Dhillon GS. Heart-lung vs. double-lung transplantation for idiopathic pulmonary arterial hypertension. Clin Transplant. 2015 Dec;29(12):1067-75. 41. Cantu E, Suzuki Y, Diamond JM, Ellis J, Tiwari J, Beduhn B, Nellen JR, Shah R, Meyer NJ, Lederer DJ, Kawut SM, Palmer SM, Snyder LD, Hartwig MG, Lama VN, Bhorade S, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, Weill D, Wilkes D, Roe D, Ware LB, Wang F, Feng R, Christie JD; Lung Transplant Outcomes Group. Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk. Am J Transplant. 2015 Dec. 42. Mooney JJ, Hedlin H, Mohabir PK, Vazquez R, Nguyen J, Ha R, Chiu P, Patel K, Zamora MR, Weill D, Nicolls MR, Dhillon GS. Lung Quality and Utilization in Controlled Donation After Circulatory Determination of Death Within the United States. Am J Transplant. 2016 Feb. 43. Yang RL, Kurian AW, Winton LM, Weill D, Patel K, Kingham K, Wapnir IL. Addressing inherited predisposition for breast cancer in transplant recipients. J Surg Oncol. 2016 Feb. 44. Mooney JJ, Weill D, Boyd JH, Nicolls MR, Bhattacharya J, Dhillon GS. Effect of Transplant Center Volume on Cost and Readmissions in Medicare Lung Transplant Recipients. Ann Am Thorac Soc. 2016 Apr 11. 4.5. Pasupneti S, Patel K, Mooney JJ, Chhatwani L, Dhillon G, Weill D. Lung transplantation following death by drowning: a review of the current literature. Clin Transplant. 2016 July, doi: 10.1111/ctr.12822. **EDITORIALS (4 TOTAL)** 1. Weill D. Role of cytomegalovirus in cardiac allograft vasculopathy. Transplant Infectious Disease 2001 Suppl 2:3:44-48. 2. Weill D and Keshavjee S. Lung Transplantation for Emphysema: Two Lungs or One? Journal of Heart and Lung Transplantation 2001; 20(7):739-742. 3.. Weill D. Donor criteria in lung transplantation: an issue revisited. Chest 2002; 121:2029-2031. 4. Weill D. Twenty years of lung transplantation: areas of improvements and challenges. Minerva Pneumologica 2003; 42:139-57. 5.. Weill D. Access to Lung Transplantation: The Long and Short of It. Am J Respir Crit Care Med. 2016 Mar 15;193(6):605-6. REVIEWS (3 TOTAL) 1. Weill D, Mack MJ, and Tennison D. Adverse effects of medications commonly administered to thoracic surgical patients. Chest Surgery Clinics of North America, Medical Complications of Thoracic Surgery, August, 1999. 2. Astor TL and Weill D. Extracorporeal photopheresis in lung transplantation. Journal of Cutaneous Medicine and Surgery 2003 Sep 9. 3. Galbraith D and Weill D. Popcom Lung and Bronchiolitis Obliterans: A Critical Appraisal. International Archives and Environmental Health 2008 June 12. 1. Weill D and Make B. Oxygen Conserving Devices. Long-Term Oxygen Therapy, New York: Marcel Dekker, 1994; 234-256. BOOK CHAPTERS/MONOGRAPHS (7 TOTAL) 2. Weill D and Zamora MR. Postoperative care in lung transplantation. Seminars in Respiratory Medicine 1996; 17(2):159-165. 3. Weill D, Rose C, and King TE. Treatment and prognosis of hypersensitivity pneumonitis. UPTODATE in Pulmonary and Critical Care Medicine, 1997, American Thoracic Society. 4. Weill D. Lung Transplantation. Textbook of Critical Care, 5th Edition, Editors: Fink, Abraham, Vincent, Kochanek, 2005. 5.. Astor TL and Weill D. Oxidative Lung Injury. Textbook of Critical Care, 5th Edition, Editors: Fink, Abraham, Vincent, Kochanek, 2005. 6. Weill D. The Clinical Aspects of the Asbestos Associated Diseases. Asbestos and Its Diseases, 1st Edition, Editors: Craighead and Gibbs, 2008. 7. Weill D. Asbestos and asbestos-related diseases. Hunter's Diseases of Occupation, 10th Edition, Editors: Baxter, Aw, Cockcroft, Durrington, and Harrington, 2010. 8. Dhillon GS and Weill D. Recipient management before transplantation. Lung Transplanation: Principles and Practice. Editors: LETTERS (5 TOTAL) 1. Weill D and Zamora MR. Comparison of the efficacy and cost effectiveness of preemptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. Journal of Heart and Lung Transplantation 2000; 19(8):815-6. 2. Weill D and Weill H. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2005 Mar 1; 171(5):527-528. 3. Calbraith DA and Weill D. Diacetyl and bronchiolitis obliterans. Am J Respir Crit Care Med 2008 Aug 1;178(3):313. 4. Finley BL, Galbraith DA, and Weill D. Comments on respiratory toxicity of diacetyl. Toxicol SCi 2008 Oct; 105(2):429-32. 5. Galbraith DA and Weill D. Authors' response to Kreiss et al. Int Arch Occup Environ Health 2010 Feb;83(2):237-40. 6. Weill D, Chatfield E, Cox A Jr, Gamble J, Gibbs G, Wylie A. In reference to Hwang et al. "The Relationship Between Various Exposure Metrics for Elongate Mineral Particles (EMP) in the Taconite Mining and Processing Industry" J Occup Envir Hyg. 2015 Jan 23. ORAL PRESENTATIONS (COMPETITIVE) (6 TOTAL) 1. Weill D. p53 Oncogene Transfers to Non-Small Cell Lung Cancers, American Association of Thoracic Surgeons, May, 1998. 2. Weill D, Torres, F, Hodges TN, and Zamora MR. Acute Native Lung Hyperinflation Following Single Lung Transplantation for Emphysema, International Society of Heart and Lung Transplantation, April, 1999. 3. Weill D, Magee M, Dewey T, and Mack MJ. Impact of Donor Gram Stain on Recipient Outcome Following Lung Transplantation, International Society of Heart and Lung Transplantation, April, 2000. 4. Weill D, Young R, And McGiffin DC. The Utility of Open Lung Biopsy Following Lung Transplantation, 4th International Congress on Lung Transplantation, September, 2000. 5. Weill D, Young R, and McGiffin DC. A Positive Donor Gram Stain Does Not Predict the Development of Pneumonia, Oxygenation, or Duration of Mechanical Ventilation Following Lung Transplantation, International Society of Heart and Lung Transplantation, April, 6. Dhillon GS, Zamora MR, Roos JE, Sheahan D, Sista RR, Van der Starre P, Weill D, Nicolls MR. Lung Transplant Airway Hypoxia: A Diathesis to Fibrosis? American Thoracic Society Annual Meeting, New Orleans, May 2010. INVITED EXTRAMURAL LECTURES AND PRESENTATIONS (19 TOTAL) June 1997 Tolerance to Acute Lung Injury, Louisiana State University Pulmonary Grand Rounds September 2000 Late Complications Following Lung Transplantation, Lung Transplantation 2000, Mount Sinai Medical Center July 2000 Current Aspects of Lung Transplantation. Medical Grand Rounds, University of Alabama-Birmingham February 2001 Lung Transplantation for Bronchioloalveolar Carcinoma, Cardiothoracic Transplantation 2001: An International Update December 2001 An Update on Immunosuppression, Indiana University/Methodist Hospital Transplant Grand Rounds February 2002 Cytomegalovirus Infections in Thoracic Transplantation, University of Texas – San Antonio Transplant Grand Rounds February 2002 Expanding the Donor Pool, Oregon Health Sciences Center Transplant Grand Rounds October 2002 Lung Transplantation: An Update, University of Colorado Health Sciences Center, Medical Grand Rounds Novemver 2002 Photopheresis in Lung Transplantation, Johns Hopkins Medical School February 2003 Lung Transplantation for COPD: Two Lungs, One, or None, Cardiothoracic Transplantation: An International Update, Vail, CO March 2003 Expanding the Donor Pool, International Meeting, American Society of Transplant Physicians and Surgeons June 2003 An Update on Bronchiolitis Obliterans Syndrome, University of Southern California Medical School, Pulmonary Grand Rounds June 2003 Post Transplant Thoracic Malignancies, Texas Transplant Society Annual Meeting September 2004 Current Aspects of Lung Transplantation, University of Texas-Southwestern, Pulmonary Grand Rounds December 2004 An Update on Lung Transplantation, University of West Virginia Medical School, Pulmonary Grand Rounds February 2006 Lung Transplantation 2006, University of California – Davis, Pulmonary Grand Rounds December 2006 Cytomegalovirus Infections Following Lung Transplantation, Stanford University, Medical Grand Rounds March 2008 Expanding the Donor Pool, Plenary Session, Transplant Growth and Collaborative Meeting, Department of Health and **Human Services** May 2008 Lung Transplantation: Where We Have Been and Where We Are Going, Stanford University, Medical Grand Rounds April 2014 The Report on Recipient Selection Consensus Document, ISHLT, San Diego, CA February 2016 The Lung Allocation Score: Morbidity, Mortality, and Resource Utilization, The Methodist Hospital, Houston, Texas April 2016 The Preoperative Selection of Lung Transplant Candidates with Malignancy, ISHLT, Washington D.C. 2014-Present Isidore Newman School New Orleans, Louisiana **BOARD OF DIRECTORS** 2015-Present Rosemary Beach Property Owners Association Rosemary Beach, Florida